No Data
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
Zhitong Hong Kong stocks early to know | The People's Bank of China revised the M1 statistics caliber. The total value of Hong Kong's overall building transaction registration in November hit a new high in 4 months.
HKEX (00388) Global Listing Services Director Xu Jingwei pointed out at the opening forum of the 9th China Biomedical Innovation and Investment Conference that HKEX continues to play an important role in assisting global biomedical companies in listing and financing.
Hong Kong stock announcement: Xiaopeng autos-W delivered a total of 30,895 smart electric cars in November, a year-on-year increase of 54%, and a month-on-month increase of 29%.
XPeng Autos-W(09868) delivered a total of 30,895 smart electric vehicles in November, a 54% year-on-year increase and a 29% month-on-month increase; hkbn (01310) has received a non-binding preliminary proposal from I Squared Asia Advisors Pte Ltd., expressing its intention to acquire 100% of the company's issued shares. The stock will resume trading on December 3.
Simcere Pharmaceutical Group's AIS-Related Drug Gets Marketing Approval in China
China Securities Co.,Ltd.: In the 2024 version of the medical insurance catalog, the number of innovative drugs added has reached a new high, balancing 'ensuring basic coverage' and 'supporting genuine innovation'.
Overall situation of the 2024 medical insurance catalog: the results are stable, meeting expectations, with a record high in the number of new innovative drugs, reflecting a balanced consideration of fund safety, public medical needs, and support for innovation.
Simcere pharma (02096.HK): Xianbixin sublingual tablets have been approved by the National Medical Products Administration for sale in china.
On December 2, Gelonghui reported that Simcere Pharma (02096.HK) announced that on December 1, 2024, Xianbixin sublingual tablets (edaravone and ruscogenin sublingual tablets) were approved by the National Medical Products Administration (NMPA) for marketing in China, intended for improving neurological symptoms, activities of daily living, and dysfunction caused by acute ischemic stroke ("AIS"). Xianbixin sublingual tablets are a neuroprotective agent composed of two active ingredients, edaravone and ruscogenin, which have antioxidant, anti-inflammatory, and synergistic effects capable of significantly reducing brain cell damage caused by AIS. This drug features a unique sublingual tablet form.
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market
